住院精神分裂症共病慢性疼痛的临床特征及影响研究:基 于疼痛评分的多维度分析

注册号:

Registration number:

ChiCTR2600116553 

最近更新日期:

Date of Last Refreshed on:

2026-01-12 15:41:39 

注册时间:

Date of Registration:

2026-01-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

住院精神分裂症共病慢性疼痛的临床特征及影响研究:基 于疼痛评分的多维度分析

Public title:

Clinical characteristics and impact of chronic pain in hospitalized schizophrenia comorbidities: multidimensional analysis based on pain scores

注册题目简写:

住院精神分裂症共病慢性疼痛的临床特征及影响研究

English Acronym:

Clinical characteristics and impact of chronic pain in hospitalized schizophrenia comorbidities

研究课题的正式科学名称:

住院精神分裂症共病慢性疼痛的临床特征及影响研究:基 于疼痛评分的多维度分析

Scientific title:

Clinical characteristics and impact of chronic pain in hospitalized schizophrenia comorbidities: multidimensional analysis based on pain scores

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

谭琪 

研究负责人:

谭琪 

Applicant:

Tan Qi 

Study leader:

Tan Qi 

申请注册联系人电话:

Applicant telephone:

+86 151 9717 0029

研究负责人电话:

Study leader's
telephone:

+86 151 9717 0029

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Tanq0029@163.com

研究负责人电子邮件:

Study leader's E-mail:

Tanq0029@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湘潭市雨湖区北二环路10号湘潭市第五人民医院

研究负责人通讯地址:

湘潭市雨湖区北二环路10号湘潭市第五人民医院

Applicant address:

Xiangtan Fifth People's Hospital, No. 10, North 2nd Ring Road, Yuhu District, Xiangtan City

Study leader's address:

Xiangtan Fifth People's Hospital, No. 10, North 2nd Ring Road, Yuhu District, Xiangtan City

申请注册联系人邮政编码:

Applicant postcode:

411100

研究负责人邮政编码:

Study leader's postcode:

411100

申请人所在单位:

湘潭市第五人民医院

Applicant's institution:

Xiangtan Fifth People's Hospital

研究负责人所在单位:

湘潭市第五人民医院

Affiliation of the Leader:

Xiangtan Fifth People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

ky20251013004

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

湘潭市第五人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Xiangtan Fifth People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-10-21 00:00:00

伦理委员会联系人:

王丽泓

Contact Name of the ethic committee:

Wang Lihong

伦理委员会联系地址:

湖南省湘潭市雨湖区北二环路10号

Contact Address of the ethic committee:

No. 10, North 2nd Ring Road, Yuhu District, Xiangtan City, Hunan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 181 6394 3988

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

湘潭市第五人民医院

Primary sponsor:

Xiangtan Fifth People's Hospital

研究实施负责(组长)单位地址:

湖南省湘潭市雨湖区北二环路10号

Primary sponsor's address:

No. 10, North 2nd Ring Road, Yuhu District, Xiangtan City, Hunan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南省

市(区县):

湘潭

Country:

China

Province:

Hunan

City:

Xiangtan

单位(医院):

湘潭市第五人民医院

具体地址:

湖南省湘潭市雨湖区北二环路10号

Institution
hospital:

Xiangtan Fifth People's Hospital

Address:

No. 10, North 2nd Ring Road, Yuhu District, Xiangtan City, Hunan Province

经费或物资来源:

自筹

Source(s) of funding:

Self-raised

研究疾病:

精神分裂症  

Target disease:

Schizophrenia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

本研究旨在通过横断面调查,明确本院住院精神分裂症患者共病慢性疼痛的患病率及临床特征,并通过6个月的前瞻性随访,纵向观察共病疼痛对患者精神症状、生活质量及生化指标的动态影响,为早期识别、风险评估与长期管理提供实证依据。  

Objectives of Study:

The aim of this study is to clarify the prevalence and clinical characteristics of comorbid chronic pain in hospitalized schizophrenia patients in our hospital through a cross-sectional survey, and to longitudinally observe the dynamic effects of comorbid pain on patients' mental symptoms, quality of life, and biochemical indicators through a 6-month prospective follow-up, providing empirical evidence for early identification, risk assessment, and long-term management.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

三组排除标准:1、合并严重躯体疾病;2、存在精神活性物质滥用或依赖史;3、存在严重认知、视听或语言障碍;4、妊娠期或哺乳期女性。

Exclusion criteria:

Three groups of exclusion criteria: 1. Complicated with severe physical diseases; 2. History of psychoactive substance abuse or dependence; 3. Severe cognitive, audio-visual or language impairment; 4. Pregnant or lactating women.

研究实施时间:

Study execute time:

From 2025-12-30 00:00:00 To 2027-12-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-20 00:00:00 To 2027-12-30 00:00:00

干预措施:

Interventions:

组别:

精神分裂症共病慢性疼痛组

样本量:

90

Group:

Chronic pain group with comorbidities of schizophrenia

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

精神分裂症非共病慢性疼痛组

样本量:

180

Group:

Schizophrenia non comorbid chronic pain group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

对照组

样本量:

270

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南省 

市(区县):

湘潭 

Country:

China

Province:

Hunan

City:

Xiangtan

单位(医院):

湘潭市第五人民医院 

单位级别:

三级 

Institution
hospital:

Xiangtan Fifth People's Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

简版McGill疼痛

指标类型:

主要指标

Outcome:

Simplified McGill Pain

Type:

Primary indicator

测量时间点:

测量方法:

问卷

Measure time point of outcome:

Measure method:

Questionnaire

指标中文名:

阳性与阴性症状

指标类型:

主要指标

Outcome:

Positive and negative symptoms

Type:

Primary indicator

测量时间点:

测量方法:

量表

Measure time point of outcome:

Measure method:

Scale

指标中文名:

卡尔加里精神分裂症抑郁

指标类型:

主要指标

Outcome:

Calgary schizophrenia depression

Type:

Primary indicator

测量时间点:

测量方法:

量表

Measure time point of outcome:

Measure method:

Scale

指标中文名:

健康调查

指标类型:

主要指标

Outcome:

Health Survey

Type:

Primary indicator

测量时间点:

测量方法:

简表(SF-36)

Measure time point of outcome:

Measure method:

Brief Form (SF-36)

指标中文名:

主观幸福感

指标类型:

主要指标

Outcome:

Subjective Well-being Neuroleptics

Type:

Primary indicator

测量时间点:

测量方法:

量表

Measure time point of outcome:

Measure method:

Scale

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

N/A

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF 和 EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF and EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-01-12 15:41:27